Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those withou ...

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

Neumora Therapeutics' shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and pessimistic thoughts in a key study, raising ...

—Major depressive disorder and treatment-resistant depression both require high levels of resources—both clinical and economic—across the spectrum of healthcare settings. A new study from ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...

In this longitudinal cohort study of older drivers, adults with major depressive disorder demonstrated distinct and riskier driving behaviors than those in the control group without depression, with ...

DRIVING under the influence of drink or drugs, including prescription drugs, is usually to blame for cases of dangerous ...

The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures ...

SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...